London
· Delayed Price · Currency is GBP · Price in USD Adverum Biotechnologies Statistics
Total Valuation
Adverum Biotechnologies has a market cap or net worth of GBP 75.50 million. The enterprise value is 10.56 million.
| Market Cap | 75.50M |
| Enterprise Value | 10.56M |
Important Dates
The next estimated earnings date is Wednesday, March 19, 2025.
| Earnings Date | Mar 19, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +70.02% |
| Shares Change (QoQ) | +0.12% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 11.57M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 0.70 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.15 |
| EV / Sales | 13.01 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.16 |
Financial Position
The company has a current ratio of 5.82, with a Debt / Equity ratio of 0.51.
| Current Ratio | 5.82 |
| Quick Ratio | 5.54 |
| Debt / Equity | 0.51 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.85 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -76.26% and return on invested capital (ROIC) is -32.50%.
| Return on Equity (ROE) | -76.26% |
| Return on Assets (ROA) | -29.83% |
| Return on Capital (ROIC) | -32.50% |
| Revenue Per Employee | 6,166 |
| Profits Per Employee | -580,299 |
| Employee Count | 121 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -46.69% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -46.69% |
| 50-Day Moving Average | 5.66 |
| 200-Day Moving Average | 7.46 |
| Relative Strength Index (RSI) | 39.71 |
| Average Volume (20 Days) | 1,655 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 6.42 |
Income Statement
In the last 12 months, Adverum Biotechnologies had revenue of GBP 746,100 and -70.22 million in losses. Loss per share was -4.11.
| Revenue | 746,100 |
| Gross Profit | -50.16M |
| Operating Income | -76.76M |
| Pretax Income | -71.06M |
| Net Income | -70.22M |
| EBITDA | -73.88M |
| EBIT | -76.76M |
| Loss Per Share | -4.11 |
Balance Sheet
The company has 114.33 million in cash and 54.66 million in debt, giving a net cash position of 59.67 million.
| Cash & Cash Equivalents | 114.33M |
| Total Debt | 54.66M |
| Net Cash | 59.67M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 107.52M |
| Book Value Per Share | 5.17 |
| Working Capital | 99.55M |
Cash Flow
In the last 12 months, operating cash flow was -63.82 million and capital expenditures -387,226, giving a free cash flow of -64.21 million.
| Operating Cash Flow | -63.82M |
| Capital Expenditures | -387,226 |
| Free Cash Flow | -64.21M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -10,287.60% |
| Pretax Margin | -9,524.40% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Adverum Biotechnologies does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -70.02% |
| Shareholder Yield | -70.02% |
| Earnings Yield | -93.00% |
| FCF Yield | -85.04% |
Stock Splits
The last stock split was on March 21, 2024. It was a reverse split with a ratio of 0.1.
| Last Split Date | Mar 21, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
Adverum Biotechnologies has an Altman Z-Score of -5.54. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.54 |
| Piotroski F-Score | n/a |